Profile change history

What changed for Petrelintide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Petrelintide identity.

16Total events
12Record additions
4Version changes
1Cited source years

Before and after

Preserved version changes

Profile updated

Petrelintide profile

We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.
After
A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.

Cited source records

Before
ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d
After
ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d, journal-pmid-42810355, ctg-observation-nct07843498-2026-11-05-9b532d149aaf, ctg-observation-nct07076030-2026-01-28-68a10be352b4

Claim citations

Before
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42810355, journal-pmid-42017294, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
Record updated

ClinicalTrials.gov record NCT07843472

ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.

Cited source date

Before
2026-10-07
After
2026-11-16

Source observed date

Before
2026-11-14
After
2026-11-16

Cited source records

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Headline citations

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Summary citations

Before
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
After
ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2]

Source snapshot commitment

Before
7839bde20c43885ca3c0ba78ceb7f2a639b702d6768d2a5fcdcf2a721f0540d4
After
26eb9ec866334a946792b0839f2306bcc8dfd707b971edc13ad9bf3520b3d5db
Profile status changed

Petrelintide profile

We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
After
An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.

Evidence note

Before
ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.
After
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.

Cited source records

Before
ctg-nct07589686-v3
After
ctg-nct07589686-v3, journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct06926842-2026-09-09-66566db76c0b, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d

Named organizations

Before
Hoffmann-La Roche [sources: ctg-nct07589686-v3]
After
Hoffmann-La Roche [sources: ctg-nct07589686-v3]; Zealand Pharma [sources: ctg-observation-nct06662539-2026-03-23-25a9d8533efb]

Claim citations

Before
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3; summary: ctg-nct07589686-v3; evidenceNote: ctg-nct07589686-v3
After
name: ctg-nct07589686-v3; aliases: ctg-nct07589686-v3; category: ctg-nct07589686-v3; status: ctg-nct07589686-v3, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b, ctg-observation-nct07843485-2026-11-05-e5fd0540362d; summary: ctg-nct07589686-v3, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b; evidenceNote: journal-pmid-42017294, ctg-observation-nct06662539-2026-03-23-25a9d8533efb, ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b
Profile updated

Petrelintide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
An amylin analogue candidate represented in ClinicalTrials.gov.
After
An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.

Collection chronology

Evidence added to PeptideScanner

Browse all 12 connected records →

Showing the latest 12 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

ClinicalTrials.gov record NCT07843472

PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
November 14, 2026
Cited source date
October 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07843485

PeptideScanner retained ClinicalTrials.gov record NCT07843485 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
November 14, 2026
Cited source date
November 5, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07843498

PeptideScanner retained ClinicalTrials.gov record NCT07843498 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
November 14, 2026
Cited source date
November 5, 2026
Evidence lane
Clinical trials
Record added

Petrelintide and the evolving role of amylin agonism in obesity.

PubMed lists PMID 42810353 in The lancet. Diabetes & endocrinology as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug petrelintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 13, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT06926842

PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
September 9, 2026
Cited source date
September 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07076030

PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
September 9, 2026
Cited source date
January 28, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06662539

PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
August 14, 2026
Cited source date
March 23, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07589686

PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
August 14, 2026
Cited source date
August 7, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07682818

PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
August 13, 2026
Cited source date
July 6, 2026
Evidence lane
Clinical trials
Record added

PubMed record PMID 42017294

PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 26, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT07338214

PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.

PeptideScanner change date
August 8, 2026
Cited source date
April 8, 2026
Evidence lane
Clinical trials